Target Price | $52.00 |
Price | $30.25 |
Potential |
71.90%
register free of charge
|
Number of Estimates | 14 |
14 Analysts have issued a price target Kymera Therapeutics Inc 2025 .
The average Kymera Therapeutics Inc target price is $52.00.
This is
71.90%
register free of charge
$112.00
270.25%
register free of charge
$30.00
0.83%
register free of charge
|
|
A rating was issued by 16 analysts: 11 Analysts recommend Kymera Therapeutics Inc to buy, 5 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Kymera Therapeutics Inc stock has an average upside potential 2025 of
71.90%
register free of charge
|
Dec '23 |
2024 Estimates |
|
---|---|---|
Revenue Million $ | 78.59 | 52.19 |
67.82% | 33.59% | |
EBITDA Margin | -206.09% | -393.68% |
39.02% | 91.02% | |
Net Margin | -196.72% | -361.42% |
47.68% | 83.72% |
16 Analysts have issued a sales forecast Kymera Therapeutics Inc 2024 . The average Kymera Therapeutics Inc sales estimate is
This results in the following potential growth metrics:
4 Analysts have issued an Kymera Therapeutics Inc EBITDA forecast 2024. The average Kymera Therapeutics Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
6 Kymera Therapeutics Inc Analysts have issued a net profit forecast 2024. The average Kymera Therapeutics Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '23 |
2024 Estimates |
|
---|---|---|
Earnings Per Share $ | -2.52 | -3.07 |
12.20% | 21.83% | |
P/E | negative | |
EV/Sales | 27.26 |
6 Analysts have issued a Kymera Therapeutics Inc forecast for earnings per share. The average Kymera Therapeutics Inc <a href=/blog/eps>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2024, the Kymera Therapeutics Inc stock is valued at an <a href=/blog/ev-sales-einfach-erklaert>EV/Sales of
This results in the following potential growth metrics and future valuations:
Kymera Therapeutics Inc...
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.